Over the last decade, there have been numerous developments and changes in treatment
practices for the management of patients with immune thrombocytopenia (ITP). This article is …

Key Clinical Points Immune Thrombocytopenia Immune thrombocytopenia (ITP) is
diagnosed in patients with a platelet count below 100,000 per cubic millimeter in whom …

Background Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton's tyrosine kinase,
may increase platelet counts in patients with immune thrombocytopenia by means of dual …

Primary immune thrombocytopenia (ITP) is an immune-mediated bleeding disorder
characterized by decreased platelet counts and an increased risk of bleeding. Multiple …

Platelets have long been recognized as key players in hemostasis and thrombosis;
however, growing evidence suggests that they are also significantly involved in cancer, the …

Background The burden of severe bleeding in adults and children with immune
thrombocytopenia (ITP) has not been established. Objectives To describe the frequency and …

Primary immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder,
characterized by a low platelet count (< 100× 109/L) in the absence of other causes …

This study compared the efficacy and safety of high-dose dexamethasone (HD-DXM) and
conventional prednisone (PDN) on the largest cohort to date as first-line strategies for newly …

Immune thrombocytopenia (ITP) is a rare disorder and meets the criteria for an orphan
disease. Expertise in the management of these patients is not widely spread. The following …

Background The oral thrombopoietin receptor agonist eltrombopag is approved for treatment
of adults with chronic immune thrombocytopenia. In the PETIT trial, we aimed to investigate …